Get the Stockscreener App
12.59
1.95%
-0.25
Bridgebio Oncology Therapeutics Inc stock is traded at $12.59, with a volume of 124.16K.
It is down -1.95% in the last 24 hours and down -0.32% over the past month.
BridgeBio Oncology Therapeutics Inc, formerly BridgeBio Oncology Therapeutics is a clinical-stage biotechnology company that aims to transform the lives of patients with cancers driven by RAS and PI3Ka, the two frequently mutated oncogenes.
See More
Previous Close:
$12.84
Open:
$12.88
24h Volume:
124.16K
Relative Volume:
0.54
Market Cap:
$1.01B
Revenue:
-
Net Income/Loss:
-
P/E Ratio:
-
EPS:
-
Net Cash Flow:
-
1W Performance:
-8.04%
1M Performance:
-0.32%
6M Performance:
+0.00%
1Y Performance:
+0.00%
1-Day Range:
$12.21
$13.02
1-Week Range:
$12.21
$14.87
52-Week Range:
$8.70
$14.87
Bridgebio Oncology Therapeutics Inc Stock (BBOT) Company Profile
Name
Bridgebio Oncology Therapeutics Inc
Sector
Industry
Phone
857 702 0377
Address
256 E. GRAND AVENUE, SUITE 104, SOUTH SAN FRANCISCO
Compare BBOT with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
BBOT
Bridgebio Oncology Therapeutics Inc
|
12.59 | 1.03B | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
452.04 | 113.14B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
741.29 | 78.49B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
877.94 | 54.76B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
397.55 | 54.51B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
INSM
Insmed Inc
|
197.01 | 41.64B | 447.02M | -1.18B | -906.14M | -6.1812 |
Bridgebio Oncology Therapeutics Inc Stock (BBOT) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-05-25 | Initiated | Morgan Stanley | Overweight |
| Sep-17-25 | Initiated | Leerink Partners | Outperform |
| Sep-15-25 | Initiated | H.C. Wainwright | Buy |
| Aug-15-25 | Initiated | Piper Sandler | Overweight |
Bridgebio Oncology Therapeutics Inc Stock (BBOT) Latest News
BridgeBio Oncology Therapeutics: Promising KRAS Drug DeveloperIn My View, At Least - Seeking Alpha
Wedbush Reiterates BridgeBio Oncology Therapeutics (BBOT) Outperform Recommendation - Nasdaq
BBOT Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Wedbush Reiterates Outperform Rating for BBOT; Price Target Unch - GuruFocus
BBOT Announces Late-Breaking Preclinical Data on BBO-10203, a First-in-Class RAS:PI3Kα Breaker, at the San Antonio Breast Cancer Symposium (SABCS) - GlobeNewswire
BridgeBio Oncology stock reaches all-time high at 14.87 USD By Investing.com - Investing.com Canada
BridgeBio Oncology initiated with an overweight at Morgan Stanley - MSN
Morgan Stanley Initiates Coverage of BridgeBio Oncology Therapeutics (BBOT) with Overweight Recommendation - Nasdaq
12 Health Care Stocks Moving In Friday's Intraday Session - Benzinga
BridgeBio Oncology: Positioned for Growth with Innovative RAS-Targeted Therapies - TipRanks
Morgan Stanley Initiates BridgeBio Oncology Therapeutics With Overweight Rating, $20 Price Target - marketscreener.com
BridgeBio Oncology initiated with an Overweight at Morgan Stanley - TipRanks
Morgan Stanley initiates coverage on BridgeBio Oncology stock with Overweight rating - Investing.com India
BBOT: All three oncology programs progressed in 2025, with major data readouts and strategic decisions set for 2026 - TradingView
BBOT: Wedbush Reiterates Outperform Rating with $25 Target | BBO - GuruFocus
Analysts Offer Insights on Healthcare Companies: Fulcrum Therapeutics (FULC) and Arrowhead Pharmaceuticals (ARWR) - The Globe and Mail
BBOT to Participate in Upcoming December Investor Healthcare Conferences - The Manila Times
BridgeBio Oncology Therapeutics Reports Q3 2025 Progress - TipRanks
Oppenheimer Maintains BridgeBio Oncology Therapeutics(BBOT.US) With Buy Rating, Maintains Target Price $22 - 富途牛牛
BridgeBio Oncology Therapeutics, Inc. (BBOT) Analyst Insights, Price Targets & Recommendations - Yahoo! Finance Canada
Decoding BridgeBio Oncology Therapeutics Inc (BBOT): A Strategic SWOT Insight - GuruFocus
Oppenheimer Maintains BridgeBio Oncology Therapeutics (BBOT) Outperform Recommendation - Nasdaq
BBOT Analyst Rating Update: Oppenheimer Lowers Price Target | BB - GuruFocus
Oppenheimer Adjusts BridgeBio Oncology Therapeutics Price Target to $22 From $23, Maintains Outperform Rating - MarketScreener
BBOT Reports Third Quarter 2025 Financial Results and Update on Corporate Progress - The Manila Times
A breakup strategy that’s inspiring clinical candidates for cancer - Chemical & Engineering News
BridgeBio Oncology Therapeutics, Inc.'s (NASDAQ:BBOT) largest shareholders are individual investors who were rewarded as market cap surged US$51m last week - Yahoo Finance
Analysts Are Bullish on Top Healthcare Stocks: CytomX Therapeutics (CTMX), AbCellera Biologics (ABCL) - The Globe and Mail
BridgeBio Oncology Therapeutics Inc expected to post a loss of 39 cents a shareEarnings Preview - TradingView
BridgeBio Oncology’s Promising Preclinical Data and Strategic Advancements Justify Buy Rating - TipRanks
BBOT to Participate in the Jefferies Global Healthcare Conference in London - The Manila Times
BBOT Announces Poster Presentations at the San Antonio Breast Cancer Symposium (SABCS) - The Manila Times
Preclinical Data Presented at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics Support Potential of BBO-10203, a First-in-Class RAS:PI3Kα Breaker That Inhibits KRAS-Mutant Tumor Growth without Inducin - The Manila Times
BridgeBio Oncology Therapeutics, Inc. (BBOT) stock price, news, quote and history - Yahoo! Finance UK
Preclinical Data Presented at the 2025 AACR-NCI-EORTC - GlobeNewswire
BBOT presents preclinical data on KRAS inhibitor BBO-11818 - BioWorld MedTech
BridgeBio Oncology announces new preclinical data on BBO-11818 study - TipRanks
BBOT Presents Preclinical Data Demonstrating Potential of BBO-11818 as a Potent panKRAS Inhibitor at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics - The Manila Times
Analysts Offer Insights on Healthcare Companies: Perspective Therapeutics (CATX), OnKure Therapeutics (OKUR) and BridgeBio Oncology Therapeutics (BBOT) - The Globe and Mail
BridgeBio Oncology Therapeutics, Inc. (BBOT) - Yahoo! Finance Canada
BridgeBio affiliate reports 784,720 BBOT shares via services - Stock Titan
Analysts Offer Insights on Healthcare Companies: Bicara Therapeutics Inc. (BCAX) and HUTCHMED (HCM) - The Globe and Mail
BBOT Announces Poster Presentations at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics - The Manila Times
Bbot announces poster presentations at the 2025 AACR-NCI-EORTC International Conference - MarketScreener
Bbot Announces Poster Presentations At The 2025 Aacr-Nci-Eortc International Conference - TradingView
BBOT Announces Poster Presentations at the 2025 - GlobeNewswire
2 Poster Presentations: BBOT to Present KRAS-targeted preclinical data at AACR-NCI-EORTC Oct 2025 - Stock Titan
BridgeBio Oncology Therapeutics, Inc. (BBOT) environment, social and governance (ESG) ratings - Yahoo
BridgeBio Oncology Therapeutics Rings the Closing Bell - Nasdaq
Bridgebio Oncology Therapeutics Inc Stock (BBOT) Financials Data
There is no financial data for Bridgebio Oncology Therapeutics Inc (BBOT). Check out other stocks for more information.
Revenue
Net Income
Cash Flow
EPS
1.08%
0.91%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):